Apollomics Inc. Class A Ordinary Shares (APLM) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · United States · ISIN KYG0411D1236

Price
20.80 USD
Market cap
60.63 m USD
P/E (2025)
–
P/S (2025)
7.13
Dividend yield
0.00 %
Net margin
-128.69 %
Return on equity (ROE)
343.13 %
Return on assets (ROA)
-162.93 %

Apollomics Inc. Class A Ordinary Shares financials

Fiscal year20242025
Revenue198,000.00 USD8.50 m USD
Gross profit198,000.00 USD8.25 m USD
Operating income-42.14 m USD-9.47 m USD
EBIT-41.13 m USD-9.47 m USD
Net income-53.86 m USD-10.94 m USD
Diluted EPS – continuing operations-58.13 USD-7.57 USD

Full history since 2019, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Apollomics Inc. Class A Ordinary Shares

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment. It also develops immuno-oncology products, such as APL-501, an anti-PD-1 antibody product candidate, which is in phase 1 clinical trial for the treatment of advanced or relapsed/refractory solid tumors; APL-502, an anti-PD-L1 antibody product candidate for the treatment of tumors; APL-810, a novel, rationally designed, ACCI recombinant vaccine for the treatment of gastrin immunogen; and APL-801, a CD40 and PD-L1 antibody product candidate for the treatment of tumors. The company was founded in 2015 and is based in Foster City, California.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.